{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-389844","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2026-09-14T11:29:42+00:00","discovered_at":"2026-09-14T11:35:00.203571+00:00","generated_at":"2026-09-14T11:35:19.597932+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Zipalertinib+chemo meets primary endpoint in Phase 3 REZILIENT3: PFS 14.5 vs 8.5 mo, HR 0.50","bullets":["Median PFS 14.5 vs 8.5 months (HR 0.50; 95% CI 0.34-0.73; P=0.00015) in first-line EGFR ex20ins NSCLC.","ORR 65.0% vs 40.3% (P<0.0001); median duration of response 14.2 vs 9.9 months.","Interim OS HR 0.72 (95% CI 0.42-1.23) at 30% maturity; follow-up ongoing.","Safety: Grade ≥3 AEs 87.1% vs 54.4%, mostly manageable hematologic; no new signals."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-389844","json":"https://secwatch.observer/filing/0001193125-26-389844.json","markdown":"https://secwatch.observer/filing/0001193125-26-389844.md","text":"https://secwatch.observer/filing/0001193125-26-389844.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526389844/0001193125-26-389844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526389844/cgem-20260913.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T11:35:19.597932+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}